ReP USP - Resultado da busca

Artigo de periodico
Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study (2024)
Pinto, Jairo Vinicius Merege de Mello Cruz; Crippa, José Alexandre de Souza ; Ceresér, Keila Maria; Vianna-Sulzbach, Miréia Fortes; Silveira Júnior, Érico de Moura; Rosa, Gabriel Santana da; Silva, Manoella Guatimuzim Testa da; Hizo, Gabriel Henrique; Medeiros, Leonardo Simão; Oliveira, Carlos Eduardo Santana de; Bristot, Giovana; Campos, Alline Cristina de ; Guimarães, Francisco Silveira ; Hallak, Jaime Eduardo Cecilio ; Zuardi, Antônio Waldo ; Yatham, Lakshmi N.; Kapczinski, Flávio; Kauer-Sant\2019anna, Márcia
Source: The Canadian Journal of Psychiatry. Unidades: FMRP, ESALQ
Subjects: TRANSTORNO BIPOLAR, HUMOR, DEPRESSÃO, CANNABIS, CANABINOIDES, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Jairo Vinicius Merege de Mello Cruz et al. Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study. The Canadian Journal of Psychiatry, v. 69, n. 4, p. 242-251, 2024Tradução . . Disponível em: https://doi.org/10.1177/07067437231209650. Acesso em: 18 nov. 2024.
APA
Pinto, J. V. M. de M. C., Crippa, J. A. de S., Ceresér, K. M., Vianna-Sulzbach, M. F., Silveira Júnior, É. de M., Rosa, G. S. da, et al. (2024). Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study. The Canadian Journal of Psychiatry, 69( 4), 242-251. doi:10.1177/07067437231209650
NLM
Pinto JVM de MC, Crippa JA de S, Ceresér KM, Vianna-Sulzbach MF, Silveira Júnior É de M, Rosa GS da, Silva MGT da, Hizo GH, Medeiros LS, Oliveira CES de, Bristot G, Campos AC de, Guimarães FS, Hallak JEC, Zuardi AW, Yatham LN, Kapczinski F, Kauer-Sant\2019anna M. Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study [Internet]. The Canadian Journal of Psychiatry. 2024 ; 69( 4): 242-251.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1177/07067437231209650
Vancouver
Pinto JVM de MC, Crippa JA de S, Ceresér KM, Vianna-Sulzbach MF, Silveira Júnior É de M, Rosa GS da, Silva MGT da, Hizo GH, Medeiros LS, Oliveira CES de, Bristot G, Campos AC de, Guimarães FS, Hallak JEC, Zuardi AW, Yatham LN, Kapczinski F, Kauer-Sant\2019anna M. Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study [Internet]. The Canadian Journal of Psychiatry. 2024 ; 69( 4): 242-251.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1177/07067437231209650
Artigo de periodico-carta/editorial
Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial] (2023)
Crippa, José Alexandre de Souza ; Guimarães, Francisco Silveira ; Zuardi, Antônio Waldo ; Hallak, Jaime Eduardo Cecilio
Source: Brazilian Journal of Psychiatry. Unidade: FMRP
Subjects: CANABINOIDES, CANNABIS, ALUCINOGÊNICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRIPPA, José Alexandre de Souza et al. Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial]. Brazilian Journal of Psychiatry. São Paulo: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.47626/1516-4446-2023-0047. Acesso em: 18 nov. 2024. , 2023
APA
Crippa, J. A. de S., Guimarães, F. S., Zuardi, A. W., & Hallak, J. E. C. (2023). Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial]. Brazilian Journal of Psychiatry. São Paulo: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.47626/1516-4446-2023-0047
NLM
Crippa JA de S, Guimarães FS, Zuardi AW, Hallak JEC. Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial] [Internet]. Brazilian Journal of Psychiatry. 2023 ; 45( 3): 201-202.[citado 2024 nov. 18 ] Available from: https://doi.org/10.47626/1516-4446-2023-0047
Vancouver
Crippa JA de S, Guimarães FS, Zuardi AW, Hallak JEC. Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial] [Internet]. Brazilian Journal of Psychiatry. 2023 ; 45( 3): 201-202.[citado 2024 nov. 18 ] Available from: https://doi.org/10.47626/1516-4446-2023-0047
Artigo de periodico
Systemic chronic treatment with cannabidiol in carioca high- and low-conditioned freezing rats in the neuropathic pain model: evaluation of pain sensitivity (2023)
Souza, Carolina Macêdo de; Maisonnette, Sílvia Soares; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza ; Zuardi, Antônio Waldo ; Landeira-Fernandez, J.; Leite-Panissi, Christie Ramos Andrade
Source: Pharmaceuticals. Unidades: FMRP, FFCLRP
Subjects: CANABINOIDES, ANSIEDADE, DOR CRÔNICA, DOENÇAS DO SISTEMA NERVOSO PERIFÉRICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Carolina Macêdo de et al. Systemic chronic treatment with cannabidiol in carioca high- and low-conditioned freezing rats in the neuropathic pain model: evaluation of pain sensitivity. Pharmaceuticals, v. 16, n. 7, p. 1-15, 2023Tradução . . Disponível em: https://doi.org/10.3390/ph16071003. Acesso em: 18 nov. 2024.
APA
Souza, C. M. de, Maisonnette, S. S., Hallak, J. E. C., Crippa, J. A. de S., Zuardi, A. W., Landeira-Fernandez, J., & Leite-Panissi, C. R. A. (2023). Systemic chronic treatment with cannabidiol in carioca high- and low-conditioned freezing rats in the neuropathic pain model: evaluation of pain sensitivity. Pharmaceuticals, 16( 7), 1-15. doi:10.3390/ph16071003
NLM
Souza CM de, Maisonnette SS, Hallak JEC, Crippa JA de S, Zuardi AW, Landeira-Fernandez J, Leite-Panissi CRA. Systemic chronic treatment with cannabidiol in carioca high- and low-conditioned freezing rats in the neuropathic pain model: evaluation of pain sensitivity [Internet]. Pharmaceuticals. 2023 ; 16( 7): 1-15.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3390/ph16071003
Vancouver
Souza CM de, Maisonnette SS, Hallak JEC, Crippa JA de S, Zuardi AW, Landeira-Fernandez J, Leite-Panissi CRA. Systemic chronic treatment with cannabidiol in carioca high- and low-conditioned freezing rats in the neuropathic pain model: evaluation of pain sensitivity [Internet]. Pharmaceuticals. 2023 ; 16( 7): 1-15.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3390/ph16071003
Artigo de periodico
The NLRP3 inflammasome in stress response: another target for the promiscuous cannabidiol (2023)
Hartmann, Alice; Vila-Verde, Carla ; Guimarães, Francisco Silveira ; Wegener, Sâmia Regiane Lourenço Joca ; Lisboa, Sabrina Francesca de Souza
Source: Current Neuropharmacology. Unidades: FMRP, FCFRP, IRI
Subjects: CANABINOIDES, INFLAMAÇÃO, TECIDO NERVOSO, DEGENERAÇÃO NEURAL, DOENÇAS DO SISTEMA NERVOSO, TRANSTORNOS PSICÓTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HARTMANN, Alice et al. The NLRP3 inflammasome in stress response: another target for the promiscuous cannabidiol. Current Neuropharmacology, v. 21, n. 2, p. 284-308, 2023Tradução . . Disponível em: https://doi.org/10.2174/1570159X20666220411101217. Acesso em: 18 nov. 2024.
APA
Hartmann, A., Vila-Verde, C., Guimarães, F. S., Wegener, S. R. L. J., & Lisboa, S. F. de S. (2023). The NLRP3 inflammasome in stress response: another target for the promiscuous cannabidiol. Current Neuropharmacology, 21( 2), 284-308. doi:10.2174/1570159X20666220411101217
NLM
Hartmann A, Vila-Verde C, Guimarães FS, Wegener SRLJ, Lisboa SF de S. The NLRP3 inflammasome in stress response: another target for the promiscuous cannabidiol [Internet]. Current Neuropharmacology. 2023 ; 21( 2): 284-308.[citado 2024 nov. 18 ] Available from: https://doi.org/10.2174/1570159X20666220411101217
Vancouver
Hartmann A, Vila-Verde C, Guimarães FS, Wegener SRLJ, Lisboa SF de S. The NLRP3 inflammasome in stress response: another target for the promiscuous cannabidiol [Internet]. Current Neuropharmacology. 2023 ; 21( 2): 284-308.[citado 2024 nov. 18 ] Available from: https://doi.org/10.2174/1570159X20666220411101217
Artigo de periodico
Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) (2022)
Souza, José Diogo Ribeiro de; Pacheco, Júlia Cozar; Rossi, Giordano Novak ; Paulo, Bruno O. de; Zuardi, Antônio Waldo ; Guimarães, Francisco Silveira ; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza ; Santos, Rafael Guimarães dos
Source: Pharmaceutics. Unidade: FMRP
Subjects: CANABINOIDES, INTERAÇÃO DE MEDICAMENTOS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, José Diogo Ribeiro de et al. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics, v. 14, p. 1-14, 2022Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics14122598. Acesso em: 18 nov. 2024.
APA
Souza, J. D. R. de, Pacheco, J. C., Rossi, G. N., Paulo, B. O. de, Zuardi, A. W., Guimarães, F. S., et al. (2022). Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics, 14, 1-14. doi:10.3390/pharmaceutics14122598
NLM
Souza JDR de, Pacheco JC, Rossi GN, Paulo BO de, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA de S, Santos RG dos. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) [Internet]. Pharmaceutics. 2022 ; 14 1-14.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3390/pharmaceutics14122598
Vancouver
Souza JDR de, Pacheco JC, Rossi GN, Paulo BO de, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA de S, Santos RG dos. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) [Internet]. Pharmaceutics. 2022 ; 14 1-14.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3390/pharmaceutics14122598
Artigo de periodico
Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: new insights of cannabidiol-mediated male reproductive toxicity (2022)
Carvalho, Renata K.; Rocha, Thiago L.; Fernandes, Fábio H.; Gonçalves, Bruno B.; Souza, Maingredy R.; Araújo, Amanda A.; Barbosa, Caio C.; Silva, Daniela M.; Campos, Hericles M.; Tomazett, Mariana V.; Ghedini, Paulo C.; Guimarães, Francisco Silveira ; Andersen, Monica L.; Santos, Fernanda C. A.; Costa, Renata Mazaro
Source: Chemico-Biological Interactions. Unidades: FMRP, FCF
Subjects: CANABINOIDES, DANO AO DNA, ESPERMATOGÊNESE, ESPERMATOZOIDES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARVALHO, Renata K. et al. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: new insights of cannabidiol-mediated male reproductive toxicity. Chemico-Biological Interactions, v. 351, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.cbi.2021.109743. Acesso em: 18 nov. 2024.
APA
Carvalho, R. K., Rocha, T. L., Fernandes, F. H., Gonçalves, B. B., Souza, M. R., Araújo, A. A., et al. (2022). Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: new insights of cannabidiol-mediated male reproductive toxicity. Chemico-Biological Interactions, 351. doi:10.1016/j.cbi.2021.109743
NLM
Carvalho RK, Rocha TL, Fernandes FH, Gonçalves BB, Souza MR, Araújo AA, Barbosa CC, Silva DM, Campos HM, Tomazett MV, Ghedini PC, Guimarães FS, Andersen ML, Santos FCA, Costa RM. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: new insights of cannabidiol-mediated male reproductive toxicity [Internet]. Chemico-Biological Interactions. 2022 ; 351[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.cbi.2021.109743
Vancouver
Carvalho RK, Rocha TL, Fernandes FH, Gonçalves BB, Souza MR, Araújo AA, Barbosa CC, Silva DM, Campos HM, Tomazett MV, Ghedini PC, Guimarães FS, Andersen ML, Santos FCA, Costa RM. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: new insights of cannabidiol-mediated male reproductive toxicity [Internet]. Chemico-Biological Interactions. 2022 ; 351[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.cbi.2021.109743
Artigo de periodico
The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors (2022)
Silva, Nicole Rodrigues; Gomes, Francisco Isaac Fernandes; Lopes, Alexandre Hashimoto Pereira; Cortez, Isadora Lopes; Santos, Jéssica Cristina dos; Silva, Conceição Elidianne Aníbal; Mechoulam, Raphael; Gomes, Felipe Villela ; Cunha, Thiago Mattar; Guimarães, Francisco Silveira
Source: Neurotherapeutics. Unidade: FMRP
Subjects: ANTINEOPLÁSICOS, CANABINOIDES, GÂNGLIOS ESPINHAIS, QUIMIOTERÁPICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Nicole Rodrigues et al. The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors. Neurotherapeutics, v. 19, n. 1, p. 434-449, 2022Tradução . . Disponível em: https://doi.org/10.1007/s13311-021-01164-w. Acesso em: 18 nov. 2024.
APA
Silva, N. R., Gomes, F. I. F., Lopes, A. H. P., Cortez, I. L., Santos, J. C. dos, Silva, C. E. A., et al. (2022). The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors. Neurotherapeutics, 19( 1), 434-449. doi:10.1007/s13311-021-01164-w
NLM
Silva NR, Gomes FIF, Lopes AHP, Cortez IL, Santos JC dos, Silva CEA, Mechoulam R, Gomes FV, Cunha TM, Guimarães FS. The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors [Internet]. Neurotherapeutics. 2022 ; 19( 1): 434-449.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s13311-021-01164-w
Vancouver
Silva NR, Gomes FIF, Lopes AHP, Cortez IL, Santos JC dos, Silva CEA, Mechoulam R, Gomes FV, Cunha TM, Guimarães FS. The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors [Internet]. Neurotherapeutics. 2022 ; 19( 1): 434-449.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s13311-021-01164-w
Artigo de periodico
CB1 receptor signalling mediates cannabidiol-induced panicolytic-like effects and defensive antinociception impairment in mice threatened by Bothrops jararaca lancehead pit vipers (2022)
Rodrigues, Bruno Mangili de Paula; Coimbra, Norberto Cysne
Source: Journal of Psychopharmacology. Unidades: FMRP, FFCLRP
Subjects: CANABINOIDES, PÂNICO, NEUROPSIQUIATRIA, SERPENTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RODRIGUES, Bruno Mangili de Paula e COIMBRA, Norberto Cysne. CB1 receptor signalling mediates cannabidiol-induced panicolytic-like effects and defensive antinociception impairment in mice threatened by Bothrops jararaca lancehead pit vipers. Journal of Psychopharmacology, v. 36, n. 12, p. 1384-1396, 2022Tradução . . Disponível em: https://doi.org/10.1177/02698811221115755. Acesso em: 18 nov. 2024.
APA
Rodrigues, B. M. de P., & Coimbra, N. C. (2022). CB1 receptor signalling mediates cannabidiol-induced panicolytic-like effects and defensive antinociception impairment in mice threatened by Bothrops jararaca lancehead pit vipers. Journal of Psychopharmacology, 36( 12), 1384-1396. doi:10.1177/02698811221115755
NLM
Rodrigues BM de P, Coimbra NC. CB1 receptor signalling mediates cannabidiol-induced panicolytic-like effects and defensive antinociception impairment in mice threatened by Bothrops jararaca lancehead pit vipers [Internet]. Journal of Psychopharmacology. 2022 ; 36( 12): 1384-1396.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1177/02698811221115755
Vancouver
Rodrigues BM de P, Coimbra NC. CB1 receptor signalling mediates cannabidiol-induced panicolytic-like effects and defensive antinociception impairment in mice threatened by Bothrops jararaca lancehead pit vipers [Internet]. Journal of Psychopharmacology. 2022 ; 36( 12): 1384-1396.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1177/02698811221115755
Artigo de periodico
Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes (2022)
Almeida, Valéria de; Seabra, Gabriela; Oliveira, Guilherme Reis de; Zuccoli, Giuliana S.; Rumin, Priscila; Fioramonte, Mariana; Smith, Bradley J.; Zuardi, Antônio Waldo ; Hallak, Jaime Eduardo Cecilio ; Campos, Alline Cristina de ; Crippa, José Alexandre de Souza ; Souza, Daniel Martins de
Source: European Archives of Psychiatry and Clinical Neuroscience. Unidade: FMRP
Subjects: CANABINOIDES, PROLIFERAÇÃO CELULAR, TRANSDUÇÃO DE SINAL CELULAR, PROTEÔMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALMEIDA, Valéria de et al. Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes. European Archives of Psychiatry and Clinical Neuroscience, v. 272, n. 7, p. 1311-1323, 2022Tradução . . Disponível em: https://doi.org/10.1007/s00406-022-01425-5. Acesso em: 18 nov. 2024.
APA
Almeida, V. de, Seabra, G., Oliveira, G. R. de, Zuccoli, G. S., Rumin, P., Fioramonte, M., et al. (2022). Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes. European Archives of Psychiatry and Clinical Neuroscience, 272( 7), 1311-1323. doi:10.1007/s00406-022-01425-5
NLM
Almeida V de, Seabra G, Oliveira GR de, Zuccoli GS, Rumin P, Fioramonte M, Smith BJ, Zuardi AW, Hallak JEC, Campos AC de, Crippa JA de S, Souza DM de. Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes [Internet]. European Archives of Psychiatry and Clinical Neuroscience. 2022 ; 272( 7): 1311-1323.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s00406-022-01425-5
Vancouver
Almeida V de, Seabra G, Oliveira GR de, Zuccoli GS, Rumin P, Fioramonte M, Smith BJ, Zuardi AW, Hallak JEC, Campos AC de, Crippa JA de S, Souza DM de. Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes [Internet]. European Archives of Psychiatry and Clinical Neuroscience. 2022 ; 272( 7): 1311-1323.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s00406-022-01425-5
Artigo de periodico
Cannabidiol impairs fear memory reconsolidation in female rats through dorsal hippocampus CB1 but not CB2 receptor interaction (2022)
Franzen, Jaqueline M.; Vanz, Felipe; Werle, Isabel; Guimarães, Francisco Silveira ; Bertoglio, Leandro J.
Source: European Neuropsychopharmacology. Unidades: FMRP, ICB
Subjects: CANABINOIDES, MEMÓRIA, SAÚDE MENTAL, ANSIEDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FRANZEN, Jaqueline M. et al. Cannabidiol impairs fear memory reconsolidation in female rats through dorsal hippocampus CB1 but not CB2 receptor interaction. European Neuropsychopharmacology, v. 64, p. 7-18, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.euroneuro.2022.08.002. Acesso em: 18 nov. 2024.
APA
Franzen, J. M., Vanz, F., Werle, I., Guimarães, F. S., & Bertoglio, L. J. (2022). Cannabidiol impairs fear memory reconsolidation in female rats through dorsal hippocampus CB1 but not CB2 receptor interaction. European Neuropsychopharmacology, 64, 7-18. doi:10.1016/j.euroneuro.2022.08.002
NLM
Franzen JM, Vanz F, Werle I, Guimarães FS, Bertoglio LJ. Cannabidiol impairs fear memory reconsolidation in female rats through dorsal hippocampus CB1 but not CB2 receptor interaction [Internet]. European Neuropsychopharmacology. 2022 ; 64 7-18.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.euroneuro.2022.08.002
Vancouver
Franzen JM, Vanz F, Werle I, Guimarães FS, Bertoglio LJ. Cannabidiol impairs fear memory reconsolidation in female rats through dorsal hippocampus CB1 but not CB2 receptor interaction [Internet]. European Neuropsychopharmacology. 2022 ; 64 7-18.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.euroneuro.2022.08.002
Artigo de periodico
Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments (2022)
Bayer, Hugo; Stern, Cristina A. J.; Troyner, Fernanda; Gazarini, Lucas; Guimarães, Francisco Silveira ; Bertoglio, Leandro J.
Source: Neuropharmacology. Unidade: FMRP
Subjects: COMPORTAMENTO, CANABINOIDES, TRANSTORNOS DA MEMÓRIA, FARMACOTERAPIA, PLASTICIDADE NEURONAL, CÓRTEX PRÉ-FRONTAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BAYER, Hugo et al. Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments. Neuropharmacology, v. 205, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.neuropharm.2021.108913. Acesso em: 18 nov. 2024.
APA
Bayer, H., Stern, C. A. J., Troyner, F., Gazarini, L., Guimarães, F. S., & Bertoglio, L. J. (2022). Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments. Neuropharmacology, 205, 1-11. doi:10.1016/j.neuropharm.2021.108913
NLM
Bayer H, Stern CAJ, Troyner F, Gazarini L, Guimarães FS, Bertoglio LJ. Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments [Internet]. Neuropharmacology. 2022 ; 205 1-11.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108913
Vancouver
Bayer H, Stern CAJ, Troyner F, Gazarini L, Guimarães FS, Bertoglio LJ. Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments [Internet]. Neuropharmacology. 2022 ; 205 1-11.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108913
Artigo de periodico
Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial (2022)
Crippa, José Alexandre de Souza ; Pacheco, Júlia Cozar; Zuardi, Antônio Waldo ; Guimarães, Francisco Silveira ; Campos, Alline Cristina de ; Osório, Flávia de Lima ; Loureiro, Sonia Regina ; Santos, Rafael Guimarães dos ; souza, José Diogo dos Santos; Ushirohira, Juliana Mayumi; Ferreira, Rafael Rinaldi; Costa, Karla Cristinne Mancini ; Scomparin, Davi Silveira; Scarante, Franciele Franco ; Santos, Isabela Pires dos; Mechoulam, Raphael; Kapczinski, Flávio; Fonseca, Benedito Antonio Lopes da ; Esposito, Danillo Lucas Alves ; Passos, Afonso Dinis Costa ; Dal-Fabbro, Amaury Lelis ; Bellissimo-Rodrigues, Fernando ; Arruda, Eurico ; Scarpelini, Sandro ; Andraus, Maristela Haddad; Nather Junior, Júlio Cesar; Wada, Danilo Tadao; Santos, Marcel Koenigkam ; Santos, Antonio Carlos dos ; Busatto Filho, Geraldo ; Hallak, Jaime Eduardo Cecilio
Source: Cannabis And Cannabinoid Research. Unidades: FMRP, FM
Subjects: COVID-19, CANABINOIDES, ENSAIO CLÍNICO, DOENÇAS INFECCIOSAS, MEDICINA INTERNA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRIPPA, José Alexandre de Souza et al. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial. Cannabis And Cannabinoid Research, v. 7, n. 5, p. 658-669, 2022Tradução . . Disponível em: https://doi.org/10.1089/can.2021.0093. Acesso em: 18 nov. 2024.
APA
Crippa, J. A. de S., Pacheco, J. C., Zuardi, A. W., Guimarães, F. S., Campos, A. C. de, Osório, F. de L., et al. (2022). Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial. Cannabis And Cannabinoid Research, 7( 5), 658-669. doi:10.1089/can.2021.0093
NLM
Crippa JA de S, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Loureiro SR, Santos RG dos, souza JD dos S, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Passos ADC, Dal-Fabbro AL, Bellissimo-Rodrigues F, Arruda E, Scarpelini S, Andraus MH, Nather Junior JC, Wada DT, Santos MK, Santos AC dos, Busatto Filho G, Hallak JEC. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial [Internet]. Cannabis And Cannabinoid Research. 2022 ; 7( 5): 658-669.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1089/can.2021.0093
Vancouver
Crippa JA de S, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Loureiro SR, Santos RG dos, souza JD dos S, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Passos ADC, Dal-Fabbro AL, Bellissimo-Rodrigues F, Arruda E, Scarpelini S, Andraus MH, Nather Junior JC, Wada DT, Santos MK, Santos AC dos, Busatto Filho G, Hallak JEC. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial [Internet]. Cannabis And Cannabinoid Research. 2022 ; 7( 5): 658-669.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1089/can.2021.0093
Artigo de periodico
Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli (2022)
Abichabki, Nathália de Lima Martins ; Zacharias, Luísa Vieira; Moreira, Natália Columbaro; Bellíssimo-Rodrigues, Fernando; Moreira, Fernanda L.; Benzi, Jhohann Richard de Lima ; Ogasawara, Tânia Mara Casare; Ferreira, Joseane Cristina; Ribeiro, Camila M.; Pavan, Fernando R.; Pereira, Leonardo Régis Leira; Brancini, Guilherme Thomaz Pereira; Braga, Gilberto Ubida Leite; Zuardi, Antonio Waldo; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza ; Lanchote, Vera Lucia ; Cantón, Rafael; Darini, Ana Lúcia da Costa ; Andrade, Leonardo Neves de
Source: Scientific Reports. Unidades: FMRP, FCFRP
Subjects: CANABINOIDES, REPOSICIONAMENTO DE FÁRMACOS, RESISTÊNCIA MICROBIANA ÀS DROGAS, SINERGISMO DE DROGAS, TESTES DE SENSIBILIDADE MICROBIANA, BACTÉRIAS GRAM-NEGATIVAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ABICHABKI, Nathália de Lima Martins et al. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. Scientific Reports, v. 12, p. 1-15, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41598-022-10393-8. Acesso em: 18 nov. 2024.
APA
Abichabki, N. de L. M., Zacharias, L. V., Moreira, N. C., Bellíssimo-Rodrigues, F., Moreira, F. L., Benzi, J. R. de L., et al. (2022). Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. Scientific Reports, 12, 1-15. doi:10.1038/s41598-022-10393-8
NLM
Abichabki N de LM, Zacharias LV, Moreira NC, Bellíssimo-Rodrigues F, Moreira FL, Benzi JR de L, Ogasawara TMC, Ferreira JC, Ribeiro CM, Pavan FR, Pereira LRL, Brancini GTP, Braga GUL, Zuardi AW, Hallak JEC, Crippa JA de S, Lanchote VL, Cantón R, Darini AL da C, Andrade LN de. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli [Internet]. Scientific Reports. 2022 ; 12 1-15.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41598-022-10393-8
Vancouver
Abichabki N de LM, Zacharias LV, Moreira NC, Bellíssimo-Rodrigues F, Moreira FL, Benzi JR de L, Ogasawara TMC, Ferreira JC, Ribeiro CM, Pavan FR, Pereira LRL, Brancini GTP, Braga GUL, Zuardi AW, Hallak JEC, Crippa JA de S, Lanchote VL, Cantón R, Darini AL da C, Andrade LN de. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli [Internet]. Scientific Reports. 2022 ; 12 1-15.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41598-022-10393-8
Artigo de periodico
HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia (2022)
Cortez, Isadora Lopes; Silva, Nicole R.; Rodrigues, Naielly S.; Pedrazzi, João Francisco Cordeiro; Del Bel, Elaine Aparecida ; Mechoulam, Raphael; Gomes, Felipe Villela ; Guimarães, Francisco Silveira
Source: Progress in Neuro-Psychopharmacology and Biological Psychiatry. Unidades: FORP, FMRP
Subjects: CANABINOIDES, ESQUIZOFRENIA, FARMACOTERAPIA, COMPORTAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CORTEZ, Isadora Lopes et al. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, v. 117, p. 1-9, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.pnpbp.2022.110553. Acesso em: 18 nov. 2024.
APA
Cortez, I. L., Silva, N. R., Rodrigues, N. S., Pedrazzi, J. F. C., Del Bel, E. A., Mechoulam, R., et al. (2022). HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 117, 1-9. doi:10.1016/j.pnpbp.2022.110553
NLM
Cortez IL, Silva NR, Rodrigues NS, Pedrazzi JFC, Del Bel EA, Mechoulam R, Gomes FV, Guimarães FS. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia [Internet]. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2022 ; 117 1-9.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.pnpbp.2022.110553
Vancouver
Cortez IL, Silva NR, Rodrigues NS, Pedrazzi JFC, Del Bel EA, Mechoulam R, Gomes FV, Guimarães FS. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia [Internet]. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2022 ; 117 1-9.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.pnpbp.2022.110553
Artigo de periodico
Augmented anandamide signalling in the substantia nigra pars reticulata mediates panicolytic-like effects in mice confronted by Crotalus durissus terrificus pit vipers (2022)
Almada, Rafael Carvalho ; Falconi-Sobrinho, Luiz Luciano ; Silva, Juliana Almeida da ; Wotjak, Carsten T.; Coimbra, Norberto Cysne
Source: Psychopharmacology. Unidade: FMRP
Subjects: ÁCIDOS ARAQUIDÔNICOS, CANABINOIDES, COBRAS, VENENOS, PÂNICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALMADA, Rafael Carvalho et al. Augmented anandamide signalling in the substantia nigra pars reticulata mediates panicolytic-like effects in mice confronted by Crotalus durissus terrificus pit vipers. Psychopharmacology, v. 239, n. 9, p. 2753-2769, 2022Tradução . . Disponível em: https://doi.org/10.1007/s00213-022-06127-3. Acesso em: 18 nov. 2024.
APA
Almada, R. C., Falconi-Sobrinho, L. L., Silva, J. A. da, Wotjak, C. T., & Coimbra, N. C. (2022). Augmented anandamide signalling in the substantia nigra pars reticulata mediates panicolytic-like effects in mice confronted by Crotalus durissus terrificus pit vipers. Psychopharmacology, 239( 9), 2753-2769. doi:10.1007/s00213-022-06127-3
NLM
Almada RC, Falconi-Sobrinho LL, Silva JA da, Wotjak CT, Coimbra NC. Augmented anandamide signalling in the substantia nigra pars reticulata mediates panicolytic-like effects in mice confronted by Crotalus durissus terrificus pit vipers [Internet]. Psychopharmacology. 2022 ; 239( 9): 2753-2769.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s00213-022-06127-3
Vancouver
Almada RC, Falconi-Sobrinho LL, Silva JA da, Wotjak CT, Coimbra NC. Augmented anandamide signalling in the substantia nigra pars reticulata mediates panicolytic-like effects in mice confronted by Crotalus durissus terrificus pit vipers [Internet]. Psychopharmacology. 2022 ; 239( 9): 2753-2769.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s00213-022-06127-3
Artigo de periodico
Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze (2022)
Fabris, Débora; Carvalho, Milene Cristina de ; Brandão, Marcus Lira ; Prado, Wiliam Alves do; Zuardi, Antônio Waldo ; Crippa, José Alexandre de Souza ; Oliveira, Amanda R. de; Lovick, Thelma A.; Genaro, Karina
Source: Journal of Psychopharmacology. Unidades: FMRP, FFCLRP
Subjects: ANSIEDADE, ANTIDEPRESSIVOS, FARMACOTERAPIA, CANABINOIDES, DIFERENÇAS SEXUAIS ANIMAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FABRIS, Débora et al. Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze. Journal of Psychopharmacology, v. 36, n. 12, p. 1371-1383, 2022Tradução . . Disponível em: https://doi.org/10.1177/02698811221125440. Acesso em: 18 nov. 2024.
APA
Fabris, D., Carvalho, M. C. de, Brandão, M. L., Prado, W. A. do, Zuardi, A. W., Crippa, J. A. de S., et al. (2022). Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze. Journal of Psychopharmacology, 36( 12), 1371-1383. doi:10.1177/02698811221125440
NLM
Fabris D, Carvalho MC de, Brandão ML, Prado WA do, Zuardi AW, Crippa JA de S, Oliveira AR de, Lovick TA, Genaro K. Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze [Internet]. Journal of Psychopharmacology. 2022 ; 36( 12): 1371-1383.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1177/02698811221125440
Vancouver
Fabris D, Carvalho MC de, Brandão ML, Prado WA do, Zuardi AW, Crippa JA de S, Oliveira AR de, Lovick TA, Genaro K. Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze [Internet]. Journal of Psychopharmacology. 2022 ; 36( 12): 1371-1383.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1177/02698811221125440
Artigo de periodico
Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects (2021)
Sartim, Ariandra Guerini; Marques, J.; Silveira, Kennia Moura; Nunes, Pedro Henrique Gobira; Guimarães, Francisco Silveira ; Wegener, G.; Wegener, Sâmia Regiane Lourenço Joca
Source: Neuropharmacology. Unidades: FMRP, FCFRP
Subjects: ANTIDEPRESSIVOS, COMPORTAMENTO ANIMAL, CANABINOIDES, DEPRESSÃO, HIPOCAMPO, ATIVIDADE MOTORA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SARTIM, Ariandra Guerini et al. Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects. Neuropharmacology, v. 195, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.neuropharm.2021.108679. Acesso em: 18 nov. 2024.
APA
Sartim, A. G., Marques, J., Silveira, K. M., Nunes, P. H. G., Guimarães, F. S., Wegener, G., & Wegener, S. R. L. J. (2021). Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects. Neuropharmacology, 195. doi:10.1016/j.neuropharm.2021.108679
NLM
Sartim AG, Marques J, Silveira KM, Nunes PHG, Guimarães FS, Wegener G, Wegener SRLJ. Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects [Internet]. Neuropharmacology. 2021 ; 195[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108679
Vancouver
Sartim AG, Marques J, Silveira KM, Nunes PHG, Guimarães FS, Wegener G, Wegener SRLJ. Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects [Internet]. Neuropharmacology. 2021 ; 195[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108679
Artigo de periodico
Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats (2021)
Estela, Airam Nicole Vivanco; Pereira, Maurício dos Santos; Guimarães, Francisco Silveira ; Del Bel, Elaine Aparecida ; Nascimento, Glauce Crivelaro do
Source: Neuropharmacology. Unidades: FORP, FMRP
Subjects: CANABINOIDES, ANALGÉSICOS, ANTICONVULSIVANTES, DOR FACIAL, NOCICEPTIVIDADE, DOENÇA DE PARKINSON
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ESTELA, Airam Nicole Vivanco et al. Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats. Neuropharmacology, v. 196, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.neuropharm.2021.108700. Acesso em: 18 nov. 2024.
APA
Estela, A. N. V., Pereira, M. dos S., Guimarães, F. S., Del Bel, E. A., & Nascimento, G. C. do. (2021). Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats. Neuropharmacology, 196. doi:10.1016/j.neuropharm.2021.108700
NLM
Estela ANV, Pereira M dos S, Guimarães FS, Del Bel EA, Nascimento GC do. Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats [Internet]. Neuropharmacology. 2021 ; 196[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108700
Vancouver
Estela ANV, Pereira M dos S, Guimarães FS, Del Bel EA, Nascimento GC do. Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats [Internet]. Neuropharmacology. 2021 ; 196[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108700
Artigo de periodico
Differential contribution of CB1, CB2, 5‐HT1A, and PPAR‐γ receptors to cannabidiol effects on ischemia‐induced emotional and cognitive impairments (2021)
Mori, Marco Aurélio; Meyer, Erika; Silva, Francielly F.; Milani, Humberto; Guimarães, Francisco Silveira ; Oliveira, Rúbia Maria Weffort de
Source: European Journal of Neuroscience. Unidade: FMRP
Subjects: CANABINOIDES, ISQUEMIA, SEROTONINA, NEUROFARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MORI, Marco Aurélio et al. Differential contribution of CB1, CB2, 5‐HT1A, and PPAR‐γ receptors to cannabidiol effects on ischemia‐induced emotional and cognitive impairments. European Journal of Neuroscience, v. 53, n. 6, p. 1738-1751, 2021Tradução . . Disponível em: https://doi.org/10.1111/ejn.15134. Acesso em: 18 nov. 2024.
APA
Mori, M. A., Meyer, E., Silva, F. F., Milani, H., Guimarães, F. S., & Oliveira, R. M. W. de. (2021). Differential contribution of CB1, CB2, 5‐HT1A, and PPAR‐γ receptors to cannabidiol effects on ischemia‐induced emotional and cognitive impairments. European Journal of Neuroscience, 53( 6), 1738-1751. doi:10.1111/ejn.15134
NLM
Mori MA, Meyer E, Silva FF, Milani H, Guimarães FS, Oliveira RMW de. Differential contribution of CB1, CB2, 5‐HT1A, and PPAR‐γ receptors to cannabidiol effects on ischemia‐induced emotional and cognitive impairments [Internet]. European Journal of Neuroscience. 2021 ; 53( 6): 1738-1751.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1111/ejn.15134
Vancouver
Mori MA, Meyer E, Silva FF, Milani H, Guimarães FS, Oliveira RMW de. Differential contribution of CB1, CB2, 5‐HT1A, and PPAR‐γ receptors to cannabidiol effects on ischemia‐induced emotional and cognitive impairments [Internet]. European Journal of Neuroscience. 2021 ; 53( 6): 1738-1751.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1111/ejn.15134
Artigo de periodico
Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls (2021)
Sami, Musa; Quattrone, Diego; Ferraro, Laura; Tripoli, Giada; Cascia, Erika La; Gayer-Anderson, Charlotte; Selten, Jean-Paul; Arango, Celso; Bernardo, Miquel; Tarricone, Ilaria; Tortelli, Andrea; Del-Ben, Cristina Marta
Source: Psychological Medicine. Unidade: FMRP
Subjects: ESQUIZOFRENIA, FÁRMACOS, CANABINOIDES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SAMI, Musa et al. Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, v. 51, n. 12, p. 2074-2082, 2021Tradução . . Disponível em: https://doi.org/10.1017/S0033291720000847. Acesso em: 18 nov. 2024.
APA
Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E. L., Gayer-Anderson, C., et al. (2021). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 51( 12), 2074-2082. doi:10.1017/S0033291720000847
NLM
Sami M, Quattrone D, Ferraro L, Tripoli G, Cascia EL, Gayer-Anderson C, Selten J-P, Arango C, Bernardo M, Tarricone I, Tortelli A, Del-Ben CM. Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls [Internet]. Psychological Medicine. 2021 ; 51( 12): 2074-2082.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1017/S0033291720000847
Vancouver
Sami M, Quattrone D, Ferraro L, Tripoli G, Cascia EL, Gayer-Anderson C, Selten J-P, Arango C, Bernardo M, Tarricone I, Tortelli A, Del-Ben CM. Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls [Internet]. Psychological Medicine. 2021 ; 51( 12): 2074-2082.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1017/S0033291720000847

USP Schools

ReP

Filtros

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Countries/Territories

Funding Agencies

Indexado em

Normalized affiliation

Non normalized affiliation

Countries of institutions of collaboration